Arbutus Biopharma (ABUS) Research & Development (2013 - 2026)
Arbutus Biopharma (ABUS) posted Research & Development of $4.1 million for Q1 2026, down 17.7% sequentially from $5.0 million in Q4 2025, and down 54.01% YoY from $9.0 million in Q1 2025.
Arbutus Biopharma (ABUS) Research & Development (2013 - 2026) Analysis & Trends
Arbutus Biopharma has reported Research & Development for 14 years, with the latest figure at $4.1 million in Q1 2026.
- Quarterly Research & Development fell 54.01% year-over-year to $4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.4 million (down 57.13% YoY) and the FY2025 annual result came in at $25.2 million, down 53.29% from the prior year.
- Research & Development slipped to $4.1 million in Q1 2026 per ABUS's latest filing, from $5.0 million in the prior quarter.
- Over five years, Research & Development peaked at $22.9 million in Q4 2022 and troughed at $4.1 million in Q1 2026.
- A 5-year average of $14.2 million and a median of $15.6 million in 2024 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2025: Research & Development surged 45.21% in 2022, then slumped 64.65% in 2025.
- Over 5 years, Research & Development stood at $22.9 million in 2022, then dropped by 23.47% to $17.6 million in 2023, then slumped by 49.84% to $8.8 million in 2024, then sank by 43.18% to $5.0 million in 2025, then slipped by 17.7% to $4.1 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $4.1 million, $5.0 million, and $5.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Arbutus Biopharma | 922.95 Mn | 830.33 Mn | - | 2.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.90 Mn |
| Mar 31, 2026 | 4.12 Mn |
| Dec 31, 2025 | 5.01 Mn |
| Sep 30, 2025 | 5.78 Mn |
| Jun 30, 2025 | 5.50 Mn |
| Mar 31, 2025 | 8.96 Mn |
| Dec 31, 2024 | 8.81 Mn |
| Sep 30, 2024 | 14.27 Mn |
| Jun 30, 2024 | 15.55 Mn |
| Mar 31, 2024 | 15.40 Mn |
| Dec 31, 2023 | 17.56 Mn |
| Sep 30, 2023 | 20.17 Mn |
| Jun 30, 2023 | 17.69 Mn |
| Mar 31, 2023 | 18.28 Mn |
| Dec 31, 2022 | 22.95 Mn |
| Sep 30, 2022 | 20.06 Mn |
| Jun 30, 2022 | 22.94 Mn |
| Mar 31, 2022 | 18.46 Mn |
| Dec 31, 2021 | 19.21 Mn |
| Sep 30, 2021 | 16.71 Mn |